Document is current
Any future updates will be listed below
-
Authors
Zhang, David K. Y. https://orcid.org/0000-0002-6999-6454
Brockman, Joshua M. https://orcid.org/0000-0003-2775-3478
Adu-Berchie, Kwasi https://orcid.org/0000-0002-1959-6794
Liu, Yutong https://orcid.org/0000-0001-5683-5451
Binenbaum, Yoav https://orcid.org/0000-0001-9901-7782
de Lázaro, Irene https://orcid.org/0000-0002-2775-0173
Sobral, Miguel C.
Tresa, Rea
Mooney, David J. https://orcid.org/0000-0001-6299-1194
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (5R01FD006589)
U.S. Department of Health & Human Services | National Institutes of Health (U01CA214369)
Gouvernement du Canada | Canadian Institutes of Health Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K00CA234959)
- License Information
-
More Information
Article History
Received: 6 April 2022
Accepted: 15 April 2024
First Online: 3 June 2024
Competing interests
: D.J.M. is an inventor in patent applications Harvard University has filed in relation to the TES technology, which has been licensed to Lyell Immunopharma (US Patent App. 18/072,449). D.J.M. has stock in Lyell Immunopharma. D.J.M, D.K.Y.Z. and J.M.B. are listed as inventors in a patent application based on the findings of this study (WO 2023/147185). The other authors declare no competing interests.
